$PSTI Oppenheimer

EQUITY RESEARCH
INITIATION OF COVERAGE

May 16, 2011 HEALTHCARE/BIOTECHNOLOGY
Stock Rating:
OUTPERFORM
Pluristem Therapeutics Inc.
12-18 mo. Price Target $5.00 Turning Medical Waste Into Medical Treasure For
PSTI - NASDAQ $2.63 Patients And Shareholders
3-5 Yr. EPS Gr. Rate NA SUMMARY
52-Wk Range $4.38-$0.94 Pluristem Therapeutics is developing placental stem cells (PLX) for the treatment of
Shares Outstanding 41.8M peripheral arterial disease. The company's proprietary 3-D bioreactor technology
Float NA appears to produce therapeutic stem cells that release multiple angiogenic factors
Market Capitalization $109.9M in response to local disease. Research by an independent group at SUNY Stony
Avg. Daily Trading Volume 327,750 Brook confirmed the potential benefit of 3-D culturing versus traditional 2-D
technologies. Pluristem reported encouraging results from an open-label study and
Dividend/Div Yield NA/NM
is finalizing the details of pivotal studies with the FDA and EMEA, which are
Fiscal Year Ends Jun anticipated to commence by year-end. We are initiating coverage with an
Book Value $1.10 Outperform rating and a $5/share price target.
2011E ROE NA
KEY POINTS
LT Debt $0.0M
Preferred $0.0M s PLX cells are an allogeneic therapy, and can be administered to the patient
immediately by the treating physician versus autologous therapy that requires
Common Equity $6M
cell harvesting, processing, and reinfusion. We see this convenience as a
Convertible Available No
substantial commercial advantage versus competing stem cell technologies
EPS Diluted Q1 Q2 Q3 Q4 Year Mult. currently in development for the same indication.
2009A -- -- -- -- (0.63) NM s Unlike embryonic stem cells, PLX cells are derived from the placenta, which is
2010A (0.11) (0.10) (0.13) (0.10) (0.44) NM medical waste, and is not considered ethically controversial.
2011E (0.08)A (0.11)A (0.07)A (0.05) (0.03) NM s CLI is a well-established indication with a clear regulatory path for approval. In
2012E (0.06) (0.06) (0.06) (0.06) (0.24) NM our view this reduces regulatory risk compared to other stem cell technologies in
development where the regulatory path is not as certain.
s We arrive at our price target via conservative NPV analysis. We see significant
potential upside to our estimates in critical limb ischemia and other indications
pursued by Pluristem.

Stock Price Performance Company Description
Pluristem Therapeutics Inc. is a leading
1 Year Price History for PSTI developer of placenta-based cell therapies. The
5
company's patented PLX (PLacental
eXpanded) cells drug delivery platform releases
4
a cocktail of therapeutic proteins in response to
3 a variety of local and systemic inflammatory
2 diseases. PLX-PAD comprehensive clinical
1 development plan has been recognized by both
0
the EMA and FDA, targeting a sub-population
Q1 Q2 Q3 Q1 Q2 of 20-million patients of Peripheral Artery
2011
Created by BlueMatrix Disease (PAD) market.

Oppenheimer & Co. Inc. does and seeks to do business with companies covered in its research reports. As
a result, investors should be aware that the firm may have a conflict of interest that could affect the
Boris Peaker, Ph.D., CFA objectivity of this report. Investors should consider this report as only a single factor in making their
212 667-8564 investment decision. See "Important Disclosures and Certifications" section at the end of this report for
Boris.Peaker@opco.com important disclosures, including potential conflicts of interest. See "Price Target Calculation" and "Key Risks
to Price Target" sections at the end of this report, where applicable.

Oppenheimer & Co Inc. 300 Madison Avenue New York, NY 10017 Tel: 800-221-5588 Fax: 212-667-8229


Table Of Contents
Investment Thesis pg. 3
Key Milestones pg. 4
Valuation pg. 4
Risks to Our Thesis and Price Target pg. 8
PLX Technology Background pg. 9
Stem Cells – A New Biologic Drug pg. 10
Peripheral Arterial Disease Background pg. 12
Clinical Data and Development Plan pg. 16
Financial Overview and Projections pg. 18
Management Biography pg. 22
Appendix: Stem Cells Primer pg. 26
Appendix: Angiogenesis Background pg. 28
Appendix: Select Clinical Studies of Cell Therapy in CLI pg. 30

2


Investment Thesis
Pluristem Therapeutics Inc. is a clinical stage biotechnology company developing
placental stem cells (PLX) for multiple indications. Unlike research that aims to
direct stem cell differentiation to form new tissue, Pluristem utilizes stem cells for
their ability to secrete complex and potent signaling molecules and to adjust their
molecular signaling to the local microenvironment. As such, Pluristem’s technology
is more analogous to a drug, and should not be confused with stem cell-based
organ/tissue regeneration. We believe that stem cells offer a dynamic drug delivery
approach that cannot be emulated via traditional pharmaceutical techniques, but
may be necessary in many regenerative applications. We highlight the following
key strengths of Pluristem’s technology:

a) Proprietary 3-D Bioreactor. Pluristem uses its proprietary 3-D bioreactor
technology (PluriX) to grow the cells in a more natural environment than current
standard 2-D techniques. We are encouraged by a confirmation from an
independent laboratory that stem cells grown in a 3-D environment produce
significantly more growth factors than their 2-D counterparts.

b) Convenient Storage and Administration. Pluristem’s technology is allogeneic
(not derived from patient cells) and does not require tissue samples from the
patient or histocompatibility matching. What this means in practice is that the PLX
cells are stored in a refrigerator and can be injected into a new patient at any time,
which is very different from requiring a sample from the patient and waiting several
weeks until those cells are cultured and returned to physician. We believe that this
administration convenience is a key commercial advantage versus competing
autologous (taken from the patient) stem cell therapies, simplifying logistics and
potentially reducing costs for the patient and the physician.

c) Clear Regulatory Path in US and EU. Pluristem received an approval for its
pivotal Phase II/III study in critical limb ischemia (CLI) from both the EMEA and the
FDA. This suggests that if the study is successful, and the safety database is
further confirmed in the IC study, then the same dataset may be used to gain
approval in UE and EU.

We arrive at our target price of $5/share for Pluristem based on an NPV analysis of
PLX in CLI. We estimate a launch in 2016, conservative pricing of $12,000/patient,
and US peak sales of $1.3B by 2025. Given the unique nature of the therapy, we
do not believe that generic competition is likely in the near future, but to be
conservative we only include cash flow through 2025, and exclude potential upside
from additional indications, premium pricing, and ex-US sales at this time.

Please see our initiation reports on IMMU, KERX, ONCY, and CLDX, also
published today.

3


Key Milestones

Event Date
Results for BONMOT-CLI (academic CLI study in Germany) May/June '11
Start Phase II study in IC 3Q11
Publication of Phase I/II PLX-PAD study data in journal 4Q11
Update on 12-month safety from Phase I/II PLX-PAD study 4Q11
Start Phase II/III Trial in CLI end of 2011
Phase II/III DSMB Update end of 2012
Completion of enrollment in Phase II/III CLI study end of 2013
Start physician IND muscle injury study 2011
Start Buerger's Phase II/III study 2011/2012
Start diabetic ulcers study 2012
Start neuropathy study 2012

Valuation
Initiating With An Outperform Rating And A $5/Share Price
Target

Peripheral Arterial Disease – A Large Market And Unmet Medical Need

Peripheral arterial disease (PAD) is an obstruction of arteries which generally
results in reduced circulation to the extremities, usually in the legs. Sedentary
lifestyle, high fat/high cholesterol diet, diabetes, inflammatory disease, and
smoking are the leading causes of PAD. According to the American Heart
Association, PAD affects ~8M Americans, and is more common at older age. CLI
(critical limb ischemia) is a severe form of PAD, with an estimated prevalence of
1
~1.1M in US, and is anticipated to grow to approximately 1.4M by 2015 . Further
estimates suggest that approximately 25-30% of CLI patients are not candidates
2,3
for interventional or surgical revascularization . PAD is also believed to be
responsible for ~160,000 – 200,000 amputations performed in the US annually.

NPV Analysis Suggests Price Target Of $5/Share

Development-stage biotechnology companies often present a challenge in
applying traditional multiple-based valuation techniques. We believe that valuation
based on an EPS multiple is not suitable for Pluristem because ongoing success in
additional indications following a potential approval in CLI would lead to increased
R&D costs and lower EPS in the initial years of commercialization, versus a less
valuable but a higher EPS scenario where these additional indications are
terminated in early development. As such, we based our valuation on an NPV

1
Prather W.R., et. al., The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment
of critical limb ischemia. Cytotherapy (2009) 00; 1-8.
2
Pignon B. Histological changes after implantation of autologous bone marrow mononuclear cells for chronic critical limb ischemia.
Bone Marrow Transplant (2007) 39:647-648.
3
Lawall H, et. al., Treatment of peripheral arterial disease using stem and progenitor cell therapy. Journal of vascular Surgery (2011)
53(2): 445-453.

4


analysis of PLX in CLI in the US. We conservatively limit our valuation to CLI in US
because the timing and probability of approval in other indications and geographies
is less certain at this time. In addition to the planned Phase II study in IC
(intermittent claudication), we anticipate that a Phase III study would be required
prior to label expansion in IC, and we will consider the upside in IC once additional
data is available and label expansion studies are ongoing. We exclude current
cash balance and European opportunities from our valuation because we believe
that the company is likely to invest the current cash balance into research and/or
partner ex-US geographies to finance the development of PLX for the US market.

We believe that PLX may gain approval based on successful results of the PLX-
CLI trial and positive safety findings in the PLX-IC study. We estimate the PLX-CLI
study to commence enrollment at the end of this year, and for both studies to
complete enrollment at the end of 2013. Adding one year for the observation
period and another year for filing and FDA review, we estimate approval late in
2015 and US market launch in early 2016. Based on the disease epidemiology
described above, we estimate the prevalence of CLI patients at 1.4M in 2015,
growing at a CAGR of 3%. We further estimate that 25% of these patients will not
be candidates for surgical revascularization, and are the target market for PLX. Our
market share assumption starts at 3% in 2016, as physicians slowly begin to
accept a novel therapy, growing to 20% in 2020. We would note that we are
utilizing a simple prevalence-based model where we do not exclude treated
patients from the future patient pool. We believe that is justifiable because PLX
therapy does not address the underlying cause of PAD, such as diabetes,
cardiovascular disease, etc., and the newly formed blood vessels are likely to
succumb to these underlying ailments just like the prior healthy blood vessels did.
Therefore, we believe that PLX is more likely to be a chronic therapy than a one-
time treatment.

We extend our model through 2025 without assigning a terminal value. Although a
terminal value may be warranted, our analysis suggests that even without a
terminal value, Pluristem is currently undervalued. We also do not see a generic
challenge as an issue for PLX given the complex nature of the therapy, but by
2025 competing technologies may present significant commercial pressure. Based
on a conservative launch price of $12,000/patient year, we arrive at peak sales of
$1.3B in 2025. To complete our valuation, we estimate COGS of $500/patient at
launch, decreasing progressively at larger scale, as well as sales and marketing
costs reaching 30% of revenue. In our taxation analysis we modeled the tax
incentive granted by the Israeli government to companies in the high tech industry.
Our model includes a full recapture of NOL ($82M at launch), followed by a 6-year
tax holiday, and 10% tax rate for the subsequent 4 years. To capture the
development risk associated with PLX, we applied an overall probability of
approval of 40%, and an additional 5% risk of market withdrawal post approval.
Applying a 15% discount rate and an estimated fully diluted share count of 70M in
mid-2012, we arrive at our target price of $5/share.

5


Exhibit 1: NPV Valuation Of PLX-CLI In US

Year 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
US CLI Prevalence (000s) 1,400 1,442 1,485 1,530 1,576 1,623 1,672 1,722 1,773 1,827
% no option patients 25% 25% 25% 25% 25% 25% 25% 25% 25% 25%
US CLI no option patients (000s) 350 361 371 382 394 406 418 430 443 457
US Market penetration 3% 6% 10% 15% 20% 20% 20% 20% 20%
US Treated Patients (000s) 11 22 38 59 81 84 86 89 91
Price per patient treated ($000s) $12 $12 $12 $13 $13 $13 $14 $14 $14
Total US Revenue ($MM) $130 $273 $477 $752 $1,054 $1,107 $1,163 $1,222 $1,284
Expenses
COGS (per patient, $) $500 $400 $350 $350 $350 $350 $350 $350 $350
COGS total ($MM) $5 $9 $13 $21 $28 $29 $30 $31 $32

R&D Internal $4 $4 $4 $4 $4 $4
R&D External $3 $5 $6 $4 $3 $3 $3 $3 $3 $3 $3 $3 $3
G&A $4 $4 $4 $4 $5 $12 $18 $25 $40 $75 $80 $80 $80 $80
Sales & Marketing $1 $2 $4 $25 $90 $109 $143 $226 $316 $332 $349 $367 $385
Total expenses $8 $12 $15 $18 $38 $114 $139 $185 $289 $423 $444 $462 $481 $500

Pre-tax cashflow ($MM) -$8 -$12 -$15 -$18 -$38 $15 $134 $293 $463 $631 $663 $701 $742 $784
Taxes
NOL ($MM) $56 $60 $63 $66 $86 $33 $0 $0 $0 $0 $0 $0 $0 $0
Effective tax rate 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 10% 10%
Taxes ($MM) $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $74 $78
After tax cashflow -$8 -$12 -$15 -$18 -$38 $15 $134 $293 $463 $631 $663 $701 $667 $706
Probability of cashflow 100% 100% 100% 100% 50% 40% 40% 40% 35% 35% 35% 35% 35% 35%
Risk-adjusted cashflow -$8 -$12 -$15 -$18 -$19 $6 $53 $117 $162 $221 $232 $245 $234 $247
Discount rate 15%
NPV ($MM) $372
NPV/share $5.30

Source: Oppenheimer & Co.

6


7


Significant Potential Upside To Our Valuation

We believe that our valuation is based on very conservative assumptions. We see
multiple potential sources of upsides to our valuation:

a) Larger Target Patient Market

We only included CLI patients that are not eligible for surgical reperfusion in our
model. However, we believe that even if the intermittent claudication (IC) study is
not successful, physicians may be more liberal in utilizing PLX therapy in patients
that may still be considered candidates for surgery given the risks, pain, and
inconvenience associated with the surgery itself.

b) Greater Market Share

Our market share assumption starts at 3% of eligible patients growing to 20%.
However, end-stage CLI patients have no alternative and are generally anticipating
an amputation in the near future. We believe that this may lead patients and
physicians to seek PLX therapy more aggressively, enabling Pluristem to capture a
substantial market share in a short period of time.

c) Premium Pricing

We modeled a price of $12,000/patient per year. This is a discount compared to
chronic biologic therapies such as TNF-alpha’s in rheumatoid arthritis, which cost
~$14-24,000/year. Alternatively, one could use cancer drug prices as a
comparator, which would imply prices in the $40-60,000 range. Last, one can use
the cost of amputation as a basis to price PLX therapy, which is on par with cancer
therapy costs. It is difficult to estimate the price of cell therapies at this time, and
the actual pricing is likely to be dependent on the clinical benefit delivered by these
treatments, but we believe that $12,000 is a very conservative estimate with room
to grow.

d) Higher Injection Frequency

Pluristem is investigating two injections of PLX four months apart, followed by an 8-
month waiting period for a total study length of 12 months in the Phase II/III study.
However, if approved, PLX may be used as a chronic therapy dosed on a more
regular basis, and a dosing frequency of once every four months seems
reasonable to us. Such chronic utilization may substantially increase the number of
injections per patient.

e) Additional Indications

Pluristem is investigating or plans to investigate PLX therapy in several indications
outside of CLI, including IC, Buerger’s Syndrome, diabetic ulcers, muscle injury,
and neuropathy. Success in any of these indications could significantly expand the
market for PLX.

f) Ex-US Opportunities

Pluristem received approval from the European Medicines Agency (EMEA) to
commence its Phase II/III CLI PLX-CLI study, and we believe that if the study is
successful, the company may gain approval in the EU in addition to US based on
the same study. We are not including ex-US opportunities in our valuation because
we believe that they are more difficult to assess at this time and Pluristem may
consider partnering certain geographies in order to further finance PLX

8


development and remain focused on the US market. A favorable ex-US partnership
may help add non-dilutive financing as well as significant upside to shareholders.

Risks To Our Thesis And Target Price
There are multiple risks and uncertainties associated with investment in
development-stage biotechnology companies. We recommend investors review
Pluristem’s regulatory filings for the detailed summary of investment risks, and
below we highlight the top three risks that relate to our thesis and price target.

Clinical Trial Risk

Pluristem must gain FDA approval (EMEA in Europe) to be able to market its
product. Our estimates for commercial launch in 2016 are predicated on success in
the Phase II/III CLI study and positive safety confirmation in the IC study. If either
of these trials do not meet their endpoints, Pluristem may have to conduct
additional clinical studies prior to commercial approval. We view the clinical trial
outcome as the highest risk associated with the company at this time. We would
like to highlight that in our view positive efficacy is not required in the IC study for
Pluristem to gain approval in the CLI indication.

Competitive Risk

There are several companies developing stem cell therapies for CLI, and if
successful, they are likely to compete for the same patients that Pluristem may
target. We see commercial competition as a moderate risk. Our view is based on
the observation that to the best of our knowledge, no head-to-head trials of
competing cell therapies are conducted or planned at this time. As such, even if
multiple stem cell therapies are approved for CLI, we believe that without head-to-
head comparison, perceived safety and convenience are likely to drive physician
prescribing decision. On that front, we believe that PLX’s convenience (simply take
a sample out of the refrigerator and inject) may make it one of the more
commercially attractive stem therapy options for patients and physicians.

Headline Risk

Valuation of development-stage biotechnology companies may sway significantly
due to headlines associated with competing technologies and/or macro trends in
healthcare. Due to the novelty of stem cell therapies, potential limited
understanding of the associated technologies by retail investors, and political
uncertainties associated with healthcare and stem cells, Pluristem’s stock may be
volatile for reasons not directly related to the company’s internal performance.

Liquidity and Small Capitalization

Pluristem is a small capitalization (<$500M) unprofitable biotechnology company.
The company may require additional capital to reach profitability, and an inability to
raise capital on favorable terms or at all may significantly impact the company’s
valuation. Pluristem’s stock may also exhibit volatility due to events not directly
related to its operations, including macroeconomic concerns, healthcare policy,
and political developments. Additionally, the stock’s liquidity may limit some
investors’ ability to acquire and sell shares in a timely fashion.

9


PLX Technology Background
PLX Technology Addresses Many Cell Stem Challenges
Pluristem’s stem cell therapy is based on Placental eXpanded (PLX) platform.
Cells are harvested from the placenta following a cesarean section (C-section).
The placenta is considered to be medical waste and is not a controversial source
of stem cells. Placentas are collected at the maternity ward, transported to
Pluristem’s facility, with cell processing commencing ≤4 hours following the C-
section. The mother is screened for viral infections prior to delivery, and the
placenta is then placed in quarantine for three weeks and screened once again
during the manufacturing phase. Following cell harvesting, stem cells are seeded
on a polystyrene discs and stacked into a 3-D bioreactor, called PluriX. The cells
are then grown in this bioreactor without the use of external growth factors. The
entire process takes approximately eight weeks from birth to final product ready for
shipping (Exhibit XX).

Exhibit 2: PLX Preparation Process

Source: Prather W.R., et. al., The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy (2009) 00; 1-8.

Unique Advantages Of 3-D Culturing Approach
Pluristem’s 3-D approach is very different from the traditional stem cell growing
techniques. Notably, the standard practice is to grow stem cells in plastic flasks,
which are filled with growth media and stacked on top of each other. The stem cells
grow at the bottom of flask surrounded by plastic on one end and growth media on
the other. This technique is often referred to as 2-D because the growing cells form
a flat layer in the flask. Scientific evidence suggests that cell-to-cell signaling (also
known as paracrine signaling) may be required for optimal stem cell growth and
development. Such signaling is believed to be absent, or highly attenuated, in 2-D
cultures due to limited cell-to-cell contact, requiring supplementation of growth
factors and other exogenous additive to maintain active stem cell proliferation.
Additionally, the lack of uniformity in cell-to-cell contact may lead to batch-to-batch
variability of the 2-D grown cells, which may be problematic for commercial medical
4
purposes .

An independent academic laboratory (not associated with Pluristem) observed that
culturing human stem cells in a 3-D cellular aggregate may lead to enrichment of
pro-angiogenic factors and may promote cellular survival compared to traditional
5
monolayer (2-D) culturing techniques . The investigators found that many of the
genes upregulated in cells grown in a 3-D environment were associated with

4
Klim J.R., A defined glycosaminoglycan-binding substratum for human pluripotent stem cells. Nature (2010) 7: 989-994.
5
Potanova I.A. et. al., Mesenchymal Stem Cells Support Migration, Extracellular Matrix Invasion, Proliferation, and
Survival of Endothelial Cells In Vitro. Tissue-Specific Stem Cells (2007) 25: 1761-1768.

10


hypoxia (oxygen starvation) and hypoxia-dependent angiogenic pathways,
including VEGF, stanniocalcin-1, placental growth factor, angiopoietin 2,
transforming growth factor, macrophage migration inhibitory factor, insulin-like
growth factor binding proteins 1 and 5, IL-8, IL-1alpha, IL-1beta, acetyl-coenzyme
A thiolase, transferrin, aldose reductase, heme oxygenase-1, and cyclooxygenase-
2 (see Appendix for overview of peripheral arterial diseases and angiogenesis). In
our view this is very encouraging data that further supports the potential benefits of
3-D cellular growth and the rationale of using PLX cells as angiogenesis therapy.

In addition to the angiogenic growth factor secretion discussion above, placental
stem cells also have low immunogenic properties. This suggests that PLX cells
may be administered to a patient without pre-requisite blood tests for HLA-
6
matching , which is commonly required for bone-marrow derived cells (hence the
need to find a matching bone marrow donor). Additionally, stem cells have been
shown to express immunosuppressive factors which suppress T-cell proliferation,
7
minimizing potential immune reaction . Placental stem cells are believed to have
an even stronger immunosuppressive effect relative to bone-marrow derived stem
8
cells . Placental stem cells have also produced encouraging pre-clinical data in
models of CLI (Critical Limb Ischemia), acute myocardial infarction, stroke, and
auto-immune disorders, as well as human studies of osteogenesis imperfecta, graft
9
vs. host disease, and CLI .

Stem Cells – A New Biologic Drug
A lot of emphasis in popular media and science literature is focused on utilizing
stem cells to grow new organs in the laboratory and permanently transplant them
into patients. While organ regeneration is certainly exciting, we believe that other
stem cell-based technologies are often overlooked. Stem cells have been shown to
participate in complex cell signaling pathways by releasing potent cell signaling
agents. Based on this research, Pluristem is utilizing stem cells as complex
biologic drugs delivered directly to the site of injury to secrete a range of
therapeutic molecules and not to replace damaged or diseased tissue directly.
Instead of injecting a single molecule (or a combination of molecules) that is typical
in traditional drug therapy, PLX cells injected into the diseased tissue are believed
to secret a complex mixture of potent drugs over a prolonged period of time. The
active agents produced by these stems cells may further be adjusted to the local
environment based on the interaction between the stem cells and local tissue,
something that is generally not possible with traditional pharmaceuticals.

Pluristem is initially applying its stem cell therapy to stimulate blood vessel growth
(angiogenesis). The cells are optimized to produce a range of cell-signaling
10
molecules (cytokines), including growth factors, which are produced by the body
naturally to stimulate the growth and development of blood vessels. Additionally,
the stem cells may also produce anti-inflammatory agents, which may be helpful in
the treatment of autoimmune and other inflammatory diseases. Many of these

6
Le Blank K., Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy (2003) 5: 485-489.
7
Jones B.J., Immunosuppression by placental indoleamine 2,3-dioxygenase: a role for mesenchymal stem cells. Placenta
(2007) 28: 1174-1181.
8
Chang C.J., Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of
interferon-gamma. Stem Cells (2006) 24: 2466–2477.
9
Horwitz M.E. et. al., Cytokines as the Major Mechanism of MSC Clinical Activity: Expanding the Spectrum of Cell Therapy.
Israel Medical Association Journal (2009) 11: 132-134.
10
Horwitz E.M., et. al., Cytokines as the Major Mechanism of MSC Clinical Activity: Expanding the Spectrum of Cell Therapy.
Israel Medical Association Journal (2009) 11: 132-134.

11


compounds are difficult to produce in the laboratory, and it may not be possible to
deliver them by traditional drug delivery techniques.

We would like to acknowledge that it is possible that a small fraction of the
delivered stem cells may differentiate into endothelial progenitor cells (EPC). EPC
are circulating cells that are believed to further differentiate into endothelial cells
(cells that line blood vessels), and may play essential role in the maintenance of
11
existing blood vessels and growth of new vessels . Research data indicates that
12 13 14 15 16
age , diabetes , high cholesterol , hypertension , smoking , and coronary
artery disease may reduce the availability of EPCs, which may further lead to
reduce integrity of exiting blood vessels and/or decrease in the rate of new vessel
formation. Multiple animal and human studies have shown that administration of
EPC derived from bone marrow may lead to both short-term and long-term
17
improvement in cardiovascular function . One caveat that we would like to add to
the EPC discussion above is that we are not aware of data that that shows the
conversion of PLX cells to EPCs, and we do not believe that such conversion is
necessary for PLX therapy to achieve its intended goal. We are simply highlighting
a potential alternative mechanism.

PLX’S Convenience Is A Key Commercial Advantage

One of the key challenges in utilizing stem cells in clinical application is the ability
of producing them in a quick and cost-effective manner. Autologous therapies
present a unique challenge whereby cells must be first harvested from the patient,
delivered to a manufacturing facility, grown and modified as necessary, formulated
for infusion, delivered to the treating physician, and infused into the patient. The
logistical process has multiple potential bottlenecks and requires at least two
physician visits (initial cell harvest and final administration). Similar logistical
challenges have been successfully addressed in autologous cancer vaccine
manufacturing, such as Dendreon’s Provenge. However, we believe that the
complexities of autologous stem cell therapy may remain a key limitation for
companies like Aastrom Biosciences and an advantage to Pluristem. Assuming a
scenario where both therapies are approved and available, we believe that the
physician is likely to choose PLX as the first treatment because the medical
diagnosis, decision, and therapy administration can all be done as part of a single
visit, instead of multiple visits. In our view Aastrom would have to show superiority
to PLX in order to convince a physician to use its therapy as first line, and we do
not anticipate head-to-head studies between the two technologies in the near
future to make a claim of superiority. As an anecdotal data point highlighting the
importance of administration convenience, we observed that Pluristem chose to
decrease the number of injections for PLX administration from 50 per visit in
European studies to 30 per visit in the US to address the US physicians’ concern
that 50 injections is too time consuming. If the 20 additional injections were viewed
as a significant inconvenience by participating physicians, despite the fact that

11
Rafii S., et. al., Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nature
Medicine (2003) 9: 702-712.
12
Rauscher F.M., et. al., Aging, progenitor cell exhaustion and atherosclerosis. Circulation (2003) 108:457-463.
13
Waltenberger J. Impaired Collateral vessel development in diabetes: potential cellular mechanisms and therapeutic
implications. Cardiovascular Research (2001) 49:554-560.
14
Hill J.M., et. al., Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. New England Journal of
Medicine (2003) 348: 593-600.
15
Vasa M. et. al., Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for
coronary artery disease. Circulatory Research (2001):89-E1-E7.
16
Kondo T. et. al., Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers.
Arteriosclerosis, Thrombosis, and Vascular Biology (2004) 24: 1442 – 1447.
17
Shnatsila E., et. al., Endothelial Progenitor Cells in Cardiovascular Disorders. Journal of the American College of Cardiology
(2007) 49:741-752.

12


most of these injections were performed by nurses and not physicians, we believe
that logistical hurdles are an even greater inconvenience then additional injections
for competing autologous stem cell technologies.

Peripheral Arterial Disease Background
PAD remains a relatively unknown disease, with approximately 75% of the
18
population unaware of its symptoms and long-term consequences . The
prevalence of PAD also increases with age (Exhibit XX), and is anticipated to grow
significantly over the next decade due to the aging of the population. Interestingly,
prior to 65 years of age, PAD predominantly affects men, but women quickly catch
up after 65 years of age.

Exhibit 3: PAD Prevalence By Age

Source: Rush University Medical Center

PAD is a progressive disease. The initial symptoms start with claudication, which is
defined as painful and tired feeling in the legs following a brisk walk that is relieved
by rest. To put this definition in perspective, approximately one third of patients
with intermittent claudication can not walk one city block without experiencing pain,
19
while another third feel leg pain during routine housework . Intermittent
claudication incidence is estimated at 5% of men and 2.5% of women over the age
20
of 60 . As stenosis increases, claudication becomes more severe, with ischemic
leg pain at rest (pain due to oxygen starvation), which is exacerbated by raising the
limb. The next stages of disease involve ulcers and gangrene, which lead to minor
(below the ankle) and major (above the ankle) amputations. The severe subset of
PAD is also known as Critical Limb Ischemia (CLI). There are two scales that are
used to classify PAD in the clinic, Fontaine and Rutherford. In exhibit XX we
provide a side-by-side comparison of both scales.

18
Hirsch A. T., et. al., Gaps in public knowledge of peripheral arterial disease. Circulation (2007) 116: 2086-2094.
19
Annex B.H. Cardiology rounds at Brigham and Women’s Hospital (2002) 6(1).
20
Shammas N.W. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vascular Health and Risk
Management (2007) 3:2; 229-234.

13


Exhibit 4: PAD Rating Scales

Fontaine Scale Rutherford Scale
Stage Symptom Grade Category Symptoms
I Asymptomatic 0 0 Asymptomatic
II a Mild Claudication I 1 Mild Claudication
Moderate - Severe I 2 Moderate Claudication
II b
Claudication I 3 Severe Claudication
II 4 Pain at Rest
III Pain at Rest
III 5 Minor Tissue Loss
IV Ulcers/Gangrege III 6 Major Tissue Loss
Source: American Heart Association

Many individuals with early stage PAD may not be aware of their condition until
they experience the initial symptoms, such as pain and tiredness in the leg and hip
muscles while walking due to lack of oxygen. While some patients initially dismiss
these early signs as simply aging-associated pain, PAD can be readily diagnosed
by a physician using one of several approaches:

Ankle-Brachial Index (ABI) is a ratio of blood pressure between the legs and the
arms using standard sphyngomanometer (blood pressure meter). A lower blood
pressure in the legs vs. the arms indicates blocked arteries. This technique is
painless, does not require specialized equipment, and can be performed during
routine physical examination. ABI results of 0.9 – 1.3 are considered
normal/acceptable, 0.8 – 0.9 suggests mild blockage, 0.5 – 0.8 moderate PAD, and
anything <0.5 is considered severe PAD. ABI readings of greater than 1.3 suggest
calcification of the artery, and for these subjects ABI is not a suitable metric.

Non-invasive imaging, which includes Doppler/ultrasound, CT scans, MRI, and
angiograms (X-ray with the use of an injected contrast agent). The exact technique
utilized often depends on the available facility and equipment.

Buerger’s test (leg elevation). The patients’ legs are elevated at 45% for a short
period of time and the change in color at the feet and toes is observed between
elevated and sitting state.

ABI Measurement Important For Assessing Clinical Trials
The introduction of imaging technologies for the assessment and monitoring of
PAD resulted in a more quantitative assessment of PAD disease and progression.
However, we would like to highlight the significance of ABI measurements. While
ABI is viewed by some physicians as a rather crude measurement, due to lack of a
unifying protocols, potential for measurement error, and the difficulty presented by
calcification, it remains a common metric for assessing PAD progression.
Research has shown that ABI correlates well with clinical outcomes such as
amputation and mortality. Specifically, chronic ischemia patients with ABI <0.5
experienced limb loss of 28% and 34% at 6 months and 12 months, respectively,

14


and an overall limb loss of 23% after one year. Overall amputation rate is
estimated at 10-40% after one year, with a mortality rate of 20% after one year, 40-
21
70% after 5 years, and 80-95% after 10 years .

Multiple studies have shown that PAD is correlated with cardiovascular disease
and overall mortality. The data indicates that patients with more severe PAD have
a greater risk of death (Exhibit XX), although the median survival varies from ~4-6
years for patients diagnosed with severe forms of the disease, to several decades
for those in early stages. The results are confounded by the difficulties of
comparing across clinical trials and the co-morbidities of the subjects. Our main
takeaways from these mortality statistics are that patients in late stage of disease
may seek PAD treatment for 5+ years, and those in earlier stages may require
chronic therapy for 10+ years (depending on the safety and efficacy of therapy).

21
Shammas N.W. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vascular Health and Risk
Management (2007) 3:2; 229-234.

15


Exhibit 5: PAD Survival Based On Disease Severity At Diagnosis From Two Independent Studies

Source: Crique M.H. et. al., New England Journal of Medicine (1992) 326:381-386

Source: McKenna et. al., Atherosclerosis (1991): 87

Therapeutic Approaches For PAD Management

There are multiple therapeutic approaches to treat PAD. The objective of the
therapy is to alleviate pain, increase function, prevent/control the underlying cause
of PAD (diabetes, high cholesterol, etc.) and reduce the probability of limb
amputation, morbidity, and mortality. The recommendation for patients in the early
stages of PAD are a better diet, exercise, improved blood sugar control for
diabetics, and weight loss as necessary. Patients with intermittent claudication
(typically cramping and pain in the calf and other leg muscles) are also given a

16


similar list of recommendations, but may have a difficult time commencing an
active exercise program since movement may trigger painful episodes, limiting
their ability to exercise. There are many drugs prescribed to provide temporary
symptomatic relief, including aspirin, ACE inhibitors, beta blockers, and cilostazol.
However, these agents may take several months to deliver their effect (Exhibit XX),
some have been found ineffective, and they fundamentally do not address the
underlying blockage of the blood vessels. Additionally, some patients may be
contra-indicated for these drugs if they have other underlying conditions such as
congestive heart failure, clotting disorders, or simply cannot tolerate the associated
side effects. When drugs are not adequate to control PAD symptoms, angioplasty
(mechanically opening blood vessels using a wire or balloon catheter) or stenting
(inserting metal mesh to keep the blood vessel open) may be employed. It is
estimated that 10-15% of PAD patients are treated with an interventional
procedure. The last option is surgery, where the surgeon may attempt to remove a
large piece of plaque by hand or simply cut out the obstructed artery and replace it
with a graft from another part of the body. In all cases surgery is considered the
last resort, and is performed in ~5% of PAD patients. Despite the range of
available therapies, the underlying occlusions generally worsen with time,
ultimately leading the patient to seek more aggressive treatment. Some patients
are not eligible for interventional procedures or vascular surgery due to old age, co-
morbidities, and vascular anatomy. To help address the need of these end-stage
PAD patients, a number of therapies are in development aimed at stimulating the
growth of new blood vessels, including PLX cells by Pluristem.

Exhibit 6: Walking Improvements With Oral Drugs in PAD
Duration of Increase in Peak Increase in Pain-Free Increase in Walking
Therapy
Therapy Walking Time Walking Time Distance
Exercise 12 weeks 123% 165%
Cilostazol 24 weeks 54%
Statins 6 months 24% 24%
Statins 12 months 42% 42%
Aspirin or
Multiple Little to no observed effect on walking
clopidogrel
Source: Shammas N.W. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vascular Health and Risk Management (2007)
3:2; 229-234.

Clinical Data And Development
Pluristem Reports Encouraging Data, Plans To Commence Phase II/III Study
This Year

Pluristem is currently conducting a Phase I/IIa study of PLX-PAD in 27 patients
with Peripheral Arterial Disease (PAD) who are not eligible for surgical reperfusion.
The open-label, multi-center, dose-ranging study is conducted at leading medical
centers in the US and Germany. The study is aimed at evaluating the safety of
PLX-PAD as well as preliminary efficacy at 3 months. Three doses are tested with
50 injections/limb in Germany and 30 injections/limb in the US (Exhibit XX).

17


Exhibit 7: Phase I / IIa Dosing
German
# of PLX Cells US Group
Dosage Group Group
Injected/Dose
(n = 15) (n = 12)
Single dose;
Low Dose 175×106 NA
50 injections
Single dose; Single dose;
Intermediate Dose 315×106
50 injections 30 injections
Single dose; 2 doses 2 weeks apart;
High Dose 595×106
50 injections 30-injections each dose
Source: Company presentation

In September 2010 the company reported encouraging interim safety update from
all 27 patients and efficacy results were reported in April 2011. In order to assess
immunogenic safety, a total 7 placentas were utilized in the study. Out of the 27
treated patients, six received repeated doses with five of the repeats from the
same placenta. The safety findings were unremarkable, with no significant adverse
events and no immune response to date. The company plans to follow the US
patients (n = 12) for 12 months and European patients (n = 15) for 21 months to
assess long term safety. From the efficacy perspective, only 1 amputation was
reported, which was two weeks after PLX-injection. This suggests an amputation
rate of 3.7%, which is below the 3-months amputation-free survival (AFS) rate of
10-25% observed in other trials. We view these data as encouraging, with a caveat
that this was an open-label study with 3-month follow-up, while FDA wants to see
AFS results at 12 months from a placebo-controlled study.

Pivotal Study In CLI To Start This Year, Other Studies Conducted In Parallel

Pluristem met with the FDA and EMEA to discuss its regulatory strategy and
received approval for its protocol to commence Phase II/III studies of PLX in CLI
patient. This multi-national, multi-center, double-blind, randomized study is
scheduled to enroll 450 patients with a 1:1 randomization to PLX and placebo.
These patients will have CLI with a grading of III-IV on the Fontaine scale and
category 4-5 on the Rutherford scale, and are not candidates for surgical
6
reperfusion. Pluristem plans to advance the intermediate dose (300×10
cells/treatment) into this study, which will be administered twice, at study
commencement and after four months. The company plans to only include centers
of excellence with prior stem cell therapy experience in this study to minimize
variations in the standard of care.

The primary endpoint in this trial is major amputation of the lower extremity
(MALE), defined as non-traumatic amputation above the ankle (trans-tibial). This
includes amputations above and below the knee, but excludes amputations of the
foot. The study will report the amputation free survival (AFS) and all-cause
mortality at 12 months. Secondary endpoints will include ABI, tissue CO2,
cutaneous O2, and quality of life metrics. Based on FDA’s comments, we believe
that the 12-months AFS endpoint could warrant approval if the trial shows a 50%
decrease in amputation rate. The study is 80% powered to show a p-value of 0.05
based on an assumed amputation rate of 22% in the control arm. Historical data
suggests 35-40% amputation rate within one year for these patients. However,
we’ve observed variability in this rate, and the RESTORE-CLI study (Aastrom’s
Phase II) reported an amputation rate of 25% on placebo at 12 months.

18


Enrollment is anticipated to commence close to the end of 2011 once the company
completes the upgrades to its manufacturing infrastructure. The study will also be
monitored by a Drug Safety Monitoring Board (DSMB), which will unblind the study
once a predetermined number of amputations has occurred. This unblinding event
target has not been announced, and will likely be made public once the trial design
is finalized. We estimate approximately two years to enroll this trial, suggesting
availability of topline data in late 2014 or early 2015. However, we anticipate the
DSMB to look at the data approximately 12 months after commencement of
enrollment, and the company may communicate the DSMB’s findings to investors.
The DSMB is authorized stop the study for safety or efficacy reasons at any time.

Intermittent Claudication Trial To Start In 2011

Pluristem received an approval from the FDA and German regulatory authorities to
commence a Phase II study of PLX in patients with Intermittent Claudication (IC).
The protocol includes a total of 135 patients split evenly across 3 groups: placebo,
6 6
two low doses (150×10 cells), and two intermediate doses (300×10 cells). The
two doses of PLX cells will be administered 4-months apart, and results will be
evaluated at 12 months. The primary endpoint is number of patients with a 50%
increase in walking distance. We believe that this is a meaningful endpoint not just
from the regulatory perspective, but also commercially.

Clear Regulatory Path Forward, Estimating Launch In 2016

Pluristem’s regulatory strategy is based on the Phase II/III study in CLI and Phase
II trial in IC. According to the company, the safety dataset from both of these trials
may be sufficient for the FDA and EMEA approval of PLX if it is consistent with
prior safety observed for this therapy. Based on comments from the company
regarding its communications with the FDA, we believe that a positive result in the
CLI study may be adequate to support US approval of PLX in CLI. Our launch
estimate date of 2016 for PLX in CLI is based on this regulatory scenario.
However, if the CLI study shows good safety but does not show a 50% reduction in
MALE (primary endpoint) with a p≤0.05, we believe that additional studies may be
necessary irrespective of the outcome from the IC study.

Pluristem also plans to conduct studies in other indications where angiogenesis
therapy is warranted, including Buerger’s disease, diabetic foot ulcer, neuropathic
pain, and muscle injury. In March 2011 Pluristem announced encouraging results
from a preclinical study of muscle injury and a collaboration with NYU Medical
Center to commence a preclinical program in diabetic foot ulcers. In our view these
are all potentially large commercial opportunities for PLX technology. We anticipate
clinical studies to commence in these indications in 2011 and/or 2012, which may
provide additional news flow while the CLI and IC studies are ongoing.

Financial Overview and Projections
Pluristem reported a cash and short-term investments balance of $45M as of
st
March 31 , 2011. We estimate the company to end June 2011 with $44M in cash
and equivalents on the balance sheet, and project a 12-month burn rate (July 2011
– June 2012) of $10M. We anticipate most of the cash to be utilized for ongoing
clinical trials as well as other corporate expenses. We believe that the current
capital should be adequate to support clinical trials and operating expenses over
the next several years, and may be sufficient to complete the Phase II/III study in

19


CLI. However, the actual cash burn may depend on success in other indications
and ongoing studies. Pluristem may be able to generate non-dilutive capital from
geographic partnerships for its PLX technology.

20


Financial Statements
Exhibit 8: Historical And Projected Income Statement

Sep-10 Dec-10 Mar-11 Jun-11 Sep-11 Dec-11 Mar-12 Jun-12
FY Ending June 30th FY09A FY10A FY11E FY12E
1QA 2QA 3QA 4QE 1QE 2QE 3QE 4QE
Revenue 0 0 0 0 0 0 0 0 0 0 0 0
Expenses
Research and development 4,792 6,123 1,501 2,186 2,145 2,000 7,832 2,600 2,800 2,900 3,000 11,300
less participation by the Office of the Chief Scientist (1,651) (1,822) (503) (608) (598) (1,000) (2,709) (900) (900) (900) (900) (3,600)
Research and development, net 3,141 4,301 998 1,578 1,547 1,000 5,123 1,700 1,900 2,000 2,100 7,700
General and administrative 3,417 3,138 756 1,246 1,152 900 4,054 900 1,000 1,000 1,000 3,900
Sales and Marketing 0 0 0 0 0 0 0 0 150 200 250 600
Operating expenses 6,558 7,439 1,754 2,824 2,699 1,900 9,177 2,600 3,050 3,200 3,350 12,200
Financing expenses (income), net 78 14 (65) (3) (86) 20 (134) 20 20 20 20 80
Net loss (6,636) (7,453) (1,689) (2,821) (2,613) (1,920) (9,043) (2,620) (3,070) (3,220) (3,370) (12,280)
Basic and diluted loss per share (0.63) (0.44) (0.08) (0.11) (0.07) (0.05) (0.29) (0.06) (0.06) (0.06) (0.06) (0.24)
Weighted average shares 10603 17005 21,012 24,897 36,677 42,233 31205 45,708 51,408 54,858 56,058 52008
Source: Company reports, Oppenheimer estimates.

21


Exhibit 9: Historical Balance Sheet
Sep-10 Dec-10 Mar-11
FY09A FY10A
ASSETS 1QA 2QA 3QA
Current Assets
Cash and equivalent 2,339 1,583 1,127 4,739 44,866
Short term bank deposit 0 913 517 0
Prepaid expenses 100 41 80 56 213
Accounts receivable from the Office of the Chief Scientist 383 706 318 361 324
Other accounts receivables 113 362 71 375 214
Total current assets 2,935 3,605 2,113 5,531 45,617
Long-term assets
Long-term deposits and restricted deposits 171 168 169 176 183
Severance pay fund 154 294 327 359 410
Property and equipment 1,203 1,555 1,756 1,816 1,943
Total long-term assets 1,528 2,017 2,252 2,351 2,536
Total Assets 4,463 5,622 4,365 7,882 48,153

LIABILITIES AND STOCKHOLDER'S EQUITY
Current Liabilities
Trade payables 487 791 673 926 1,283
Accrued expenses 81 118 157 85 107
Other accounts payable 272 372 400 468 515
Total current liabilities 840 1,281 1,230 1,479 1,905

Long-term liabilities
Long-term obligations 23
Accrued severance pay 206 360 403 420 503

STOCKHOLDER'S EQUITY
Common stock par value 0 0 0 0 0
Additional paid-in capital 36,046 44,086 44,526 50,598 92,973
Accumulated deficit during development stage (32,652) (40,105) (41,794) (44,615) (47,228)
Total stockholder's equity 3,394 3,981 2,732 5,983 45,745
Source: Company reports.

22


Management Biography
Zami Aberman
Chairman and Chief Executive Office
Mr. Aberman joined Pluristem in September 2005 as Chairman and CEO and
changed the Company’s strategy towards cellular therapeutics. Mr. Aberman's
vision to use the maternal section of the Placenta (Decidua) as a source for cell
therapy, combined with Pluristem’s 3D culturing technology, led to the
development of company unique products.

Mr. Aberman has 20 years of experience in marketing and management in the high
technology industry. He has held positions of Chief Executive Officer and
Chairman in Israel, the USA, Europe, Japan and Korea. He has operated within
high-tech global companies in the fields of automatic optical inspection, network
security, video over IP, software, chip design and robotics. Mr. Aberman serves as
the Chairman of Rose Hitech Ltd., a private investment company. He has served in
the past as the Chairman of VLScom Ltd., a private company specializing in video
compression for HDTV and video over IP and as a Director of Ori Software Ltd., a
company involved in data management. Prior to that, he served as the President
and CEO of Elbit Vision Systems (EVSNF.OB), which supplies inspection systems
for the microelectronic industry.

Mr. Aberman has served as President and CEO of Netect Ltd., specializing in the
field of internet security software and was the Co-Founder, President and CEO of
Associative Computing Ltd., which developed an associative parallel processor for
real-time video processing. He has also served as Chairman of Display Inspection
Systems Inc., specializing in laser based inspection machines and as President
and CEO of Robomatix Technologies Ltd. (RBMXF.OB).

In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field
from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical
Engineering from Ben Gurion University in Israel.

Yaky Yanay
Vice President of Finance and Chief Financial Officer
Prior to joining Pluristem, Mr. Yanay was the Chief Financial Officer of Elbit Vision
System Ltd. (EVSNF.OB), a company engaged in automatic optical inspection. He
has extensive experience in the financing and management of technology
companies. He played a major role in planning and executing a turn-around plan
for Elbit Vision System, including the completion of three acquisitions and the
raising of more than $20 million, resulting in a tripling of the company’s revenues
and attaining profitability.

Mr. Yanay began his financial career at Ernst & Young Israel in 1999, where he
served as a manager of audit groups for the technology sector. He joined Ernst
&Young’s financial team after serving in the Israeli Ministry of Foreign Affairs since

23


1993. Mr. Yanay holds a bachelor’s degree with honor in business administration
and accounting from the College of Management Studies in Rishon Le Zion, Israel
and is a Certified Public Accountant in Israel.

William R. Prather RPh, MD,
Senior VP Corporate Development
William R. Prather RPh, MD, is a Registered Pharmacist as well as a Board
Certified Internist and Geriatrician. Dr. Prather received his BS in Pharmacy (1970)
and medical degree (1973) from the University of Missouri. He practiced internal
medicine in the Kansas City, MO and Vail, CO areas until leaving Internal Medicine
in 1987 to pursue a Fellowship in Geriatric Medicine at Harvard University. He
completed this Fellowship in 1989.

In 1992 Dr. Prather left the practice of medicine to pursue a career in the financial
industry where he has held Senior Healthcare research positions for a variety of
investment banks. Dr. Prather co-founded Panacos, Inc. (NASDAQ:PANC), a
public pharmaceutical company. Additionally, he has been on the Boards of
several public and private companies, including Boston Biomedica Inc. (a public
medical diagnostics company), PriMed (a private medical device company), MdBio
(a Maryland healthcare venture firm), and sat on the Advisory Board of MDS
Capital Management (a Canadian venture firm).

Frida Grynspan, PhD,
Vice President of Research & Development
Prior to joining Pluristem, Dr. Grynspan served as Vice President of R&D of a
pioneering cell therapy company in Israel, where she was instrumental in bringing
its first cell therapy product to a multinational, multi-center Phase III clinical trial
and participated in the development of its pipeline. Before that, Dr. Grynspan
served as Senior Scientist at Intelligene Ltd., a developer of molecular biology
diagnostic and therapeutic tools, and as an instructor and biochemist at Harvard
Medical School. Dr. Grynspan has extensive experience in the fields of
biochemistry, cell biology and molecular biology and has authored numerous
scientific papers in the fields of autoimmune and degenerative diseases.

Dr. Grynspan earned her Ph.D. in Chemistry/Biochemistry from the University of
Illinois, Chicago and her post-doctoral degree from Harvard Medical
School/McLean Hospital, where she worked in the areas of Multiple Sclerosis and
Alzheimer's Disease.

Chaya Mazouz
Vice President of Clinical and Regulatory Affairs
Prior to joining Pluristem, Chaya Mazouz held the position of Clinical Operations
Director for Medgenics, a clinical-stage biopharmaceutical company involving gene
therapy, where she engineered Phase I/II clinical studies. Previously, Ms. Mazouz
served as Clinical Manager for TransPharma Medical, a drug delivery company,

24


where she was responsible for managing all of the company's clinical activities. In
previous positions, Ms. Mazouz led a multi-center Phase II study for Pharmos, a
pharmaceutical company, and was CRA and Project Manager at IDgene, a startup
company engaged in gene discovery.

Ms. Chaya Mazouz received her BSc in Nursing and MA in Philosophy of Science
from the Hebrew University in Jerusalem and is a registered Nurse. Ms. Mazouz
joined Pluristem in August 2008 to lead the Company’s clinical trials.

Amit Avrahami
Vice President of Operations and Production
Mr. Avrahami brings has 20 years of experience in Operations and Production
management in various industries such as: Pharmaceutical, Hi-Tech, Medical
Devices and Bio-Tech. Prior to joining Pluristem, Mr. Avrahami was "Site Manager
& Director of Operations" at Colbar Life Science, a Johnson & Johnson subsidiary,
which develops and produces Purified Collagen products. In his position Mr.
Avrahami upgraded the Operations system, dramatically improving product quality
and reducing the product costs. Previously, Mr. Avrahami was part of the team that
established the Operations division at Verint, a Hi-Tech subsidiary of Comverse.
He scaled-up the operations & production capability from $50 Million to $130
million.

Mr. Avrahami holds a Bachelor's Degree in Industrial Management from Shenkar
College, Israel and a Master's in Business Administration from Heriot-Watt
University, England.

Efrat Livne Hadass
Vice President of Human Resources
Ms. Livne-Hadass joined Pluristem in 2007 and is responsible for all aspects of
Human Resources management, including recruitment, professional training, and
well being. Prior to joining Pluristem and during the years 2001-2005, Efrat held the
position of Human Resources Manager at Elbit Vision Systems, a company
engaged in automatic optical inspection, located in Yokneam, Israel. While holding
that position, she was involved in some major challenges and change processes
which the company was going through, including managing HR in a small yet
global and public company.

Ms. Livne-Hadass holds an Executive M.A for Human Resources managers from
the department of Labor Studies, Tel-Aviv University and a B.Sw. degree from the
Haifa University, majoring in public healthcare services.

25


Daya Lettvin
Director of Investor & Media Relations
Daya Lettvin is the Investor and Media Relations Director of Pluristem
Therapeutics. In this position, Mrs. Lettvin is involved in investor relations, media
outreach, marketing communication, business development and reimbursement for
cellular therapies. When Mrs. Lettvin first arrived at Pluristem Therapeutics in
2005, she created the Quality Assurance and Quality Control Department, bringing
her extensive experience in the biotechnology and pharmaceutical industry. Prior
to working at Pluristem, she spent seven years in various scientific positions at
Merck & Co. Inc, focusing on the quality of biological pharmaceutical products.
Mrs. Lettvin received her honorary bachelor’s degree in Biological Sciences from
Rutgers University.

26


Appendix
Stem Cells Primer
All living organisms are composed of cells. While the size, shape, and
functionalities of the cells found in complex, multi-cellular organisms may differ
substantially, all these cells trace their origin to a zygote (Exhibit XX). A zygote is
the initial cell formed from the genetic combination of gamete cells from the two
parents. In mammals the zygote begins to divide into multiple cells shortly after
fertilization, with each of the nascent cells carrying the entire genetic content of the
original zygote. After three days the ball of cells is called a morula. The cells in the
morula begin to secrete a fluid, which spreads the cells into a sac called
blastocycst. As the cells grow and divide, each division produces a copy of the
parent cell which can either produce more copies of itself or specialize into a
specific cell type. Cells that are unspecialized and can produce identical copies of
themselves are called stem cells.

Exhibit 10: Progression Of Stem Cell Development

Source: www.wikipedia.org.

Stem cells have two defining characteristics: a) they can undergo division and
create identical copies of themselves, often after a long period of inactivity, and b)
they can differentiate into more specialized cells. Stem cells are often defined by
their potency, which is the range of cells they could potentially become.

Totipotent cell is the most undifferentiated stem cell. A totipotent cell can produce
all other stem cells and can develop into a viable organism. The splitting of
topipotent cells shortly after fertilization can result in multiple identical births, such
as twin and triplets.

Pluripotent stem cells descend from totipotent cells and can develop into all the
tissues of the organism. Their ability to differentiate into any somatic organ cell
type makes them a focus of a lot of regenerative medicine research with the aim of

27

$PSTI Oppenheimer

Recommended

Recommended

More Related Content

Similar to $PSTI Oppenheimer

Similar to $PSTI Oppenheimer (20)

More from James Hilbert

More from James Hilbert (20)

Recently uploaded

Recently uploaded (20)

$PSTI Oppenheimer